Impact of Growth Hormone Co-Treatment in Patients with Diminished Ovarian Reserve on In-Vitro Fertilisation Outcomes


Karacin P., ÖZELÇİ R., Kumcu E., Kaplanoglu D. K., DİLBAZ S., ÜSTÜN Y.

Journal of the College of Physicians and Surgeons Pakistan, cilt.35, sa.3, ss.278-281, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 3
  • Basım Tarihi: 2025
  • Doi Numarası: 10.29271/jcpsp.2025.03.278
  • Dergi Adı: Journal of the College of Physicians and Surgeons Pakistan
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.278-281
  • Anahtar Kelimeler: Controlled ovarian hyperstimulation, Growth hormone, In-vitro fertilisation, Clinical pregnancy rate
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: To assess the efficacy of growth hormone (GH) co-treatment during controlled ovarian stimulation for in-vitro fertilisation (IVF). Study Design: Descriptive analytical. Place and Duration of the Study: Department of Gynaecology, Etlik Zubeyde Hanim Training and Research Hospital, Ankara, Turkiye, from January 2010 to 2023. Methodology: A total of 191 women with diminished ovarian reserve (DOR) who underwent IVF cycles were included in the study. Eightynine patients with DOR who received GH during the study period were designated as the study group (Group A), and the 102 patients with DOR who did not receive GH were chosen as the control group (Group B). Chi-square and Mann-Whitney U tests were used to compare groups' variables. Results: The Group B's basal estradiol and FSH levels were higher than those of Group A. No significant correlation was found in regards to number of 2PNs (pro-nuclear), and the count of collected oocytes. The clinical pregnancy rate of the groups was comparable [(n = 13 (27.7%) vs. n = 19 (35.2%), p = 0.417)]. Conclusion: This study has shown that the clinical pregnancy rate did not increase significantly in the GH group.